Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash from Operations: 2024-2025

Historic Cash from Operations for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to -$13.3 million.

  • Pyxis Oncology's Cash from Operations rose 9.46% to -$13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.4 million, marking a year-over-year change of. This contributed to the annual value of -$57.7 million for FY2024, which is 18.44% up from last year.
  • Pyxis Oncology's Cash from Operations amounted to -$13.3 million in Q3 2025, which was up 23.09% from -$17.3 million recorded in Q2 2025.
  • Pyxis Oncology's 5-year Cash from Operations high stood at -$3.0 million for Q2 2024, and its period low was -$22.5 million during Q1 2025.
  • Its 2-year average for Cash from Operations is -$15.8 million, with a median of -$17.3 million in 2025.
  • Data for Pyxis Oncology's Cash from Operations shows a peak YoY increase of 9.46% (in 2025) and a maximum YoY decrease of 474.09% (in 2025) over the last 5 years.
  • Pyxis Oncology's Cash from Operations (Quarterly) stood at -$19.3 million in 2024, then climbed by 9.46% to -$13.3 million in 2025.
  • Its last three reported values are -$13.3 million in Q3 2025, -$17.3 million for Q2 2025, and -$22.5 million during Q1 2025.